BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Oct. 28, 2004
View Archived Issues
Although Vioxx Troubled, Cox-2 Area Still Of Interest
Read More
FDA Approves Shire's Phosphate Binder Fosrenol In Renal Disease
Read More
Other News To Note
Read More
Pharmasset, Roche Sign HCV Agreement Worth Up To $300M
Pharmasset Inc. could receive up to $168 million in milestone payments and maybe much more, after licensing its preclinical hepatitis C drug program to F. Hoffmann-La Roche Ltd. (BioWorld Today)
Read More
Paratek, Serono In $38M-Plus Collaboration For MS Drugs
Read More